IL-4 Superkine

IL-4 Superkine refers to a class of engineered Interleukin-4 (IL-4) variants designed with significantly enhanced binding affinity for the Interleukin-4 receptor alpha (IL-4Rα) subunit. Originally developed through directed evolution at Stanford University and licensed by Medicenna Therapeutics, these "Superkines" are modified to bypass the need for specific co-receptors or to bind more tightly to their primary target. The lead therapeutic candidate in this category, MDNA413, is a dual IL-4/IL-13 antagonist. It is engineered to bind IL-4Rα with high affinity but is unable to recruit the secondary signaling chains (the common gamma chain or IL-13Rα1), thereby effectively blocking the signaling of both IL-4 and IL-13. These cytokines are key drivers of the immunosuppressive tumor microenvironment and Th2-mediated inflammation. By inhibiting these pathways, IL-4 Superkines aim to repolarize tumor-associated macrophages and enhance anti-tumor immune responses in various solid tumors.

Other names

Engineered IL-4High-affinity IL-4 variant